Navigation Links
Bisexuality not a transitional phase among women, according to new research
Date:1/15/2008

-- but more than half of these women switched back to bisexual or unlabeled by the end.

  • By year 10, most of the women were involved in long-term (i.e., more than a year in length) monogamous relationships -- 70 percent of the self-identified lesbians, 89 percent of the bisexuals, 85 percent of the unlabeled women and 67 percent of those who were then calling themselves heterosexual.

  • Women's definitions of lesbianism appeared to permit more flexibility in behavior than their definitions of heterosexuality. For example, of the women who identified as lesbian in the last round of interviews, 15 percent reported having sexual contact with a man during the prior two years. In contrast, none of the women who settled on a heterosexual label at that point reported having sexual contact with a woman within the previous two years.

"This provides further support for the notion that female sexuality is relatively fluid and that the distinction between lesbian and bisexual women is not a rigid one," Diamond wrote.


'/>"/>

Contact: Pam Willenz
pwillenz@apa.org
202-336-5707
American Psychological Association
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Seabrook House Opens Transitional Living Facility: Seabrook West
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
4. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
5. Cytopia Commences Phase II Cancer Drug Study
6. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
7. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
8. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
9. Early Phase II results show bosutinib safe, effective for CML
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 1American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 2American Heart Association Late Breaking Clinical Trial Report 3A Tests Predict Which Patients Are Resistant to Anti Clotting Therapy During Angioplas 61370 3Love Hormone May Trigger Jealousy Too 61369 1Love Hormone May Trigger Jealousy Too 61369 2While Most Businesses are Laying Off Their Employees The Logo Loft Continues to Hire U S Graphic Designers 61366 1While Most Businesses are Laying Off Their Employees The Logo Loft Continues to Hire U S Graphic Designers 61366 2